[go: up one dir, main page]

AR036258A1 - Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto. - Google Patents

Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto.

Info

Publication number
AR036258A1
AR036258A1 ARP020103032A ARP020103032A AR036258A1 AR 036258 A1 AR036258 A1 AR 036258A1 AR P020103032 A ARP020103032 A AR P020103032A AR P020103032 A ARP020103032 A AR P020103032A AR 036258 A1 AR036258 A1 AR 036258A1
Authority
AR
Argentina
Prior art keywords
compound
lower alkyl
optionally substituted
alkyl
branched
Prior art date
Application number
ARP020103032A
Other languages
English (en)
Inventor
Bernard Gaudilliere
Remi Lavalette
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR036258A1 publication Critical patent/AR036258A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto 1-alquil o 1-cicloalquil-triazolo [4-3-a] quinazolin-5-onas de la fórmula (1) en donde R1 se selecciona de: hidroxilo, halógeno, nitro, mercapto, ciano o carboxilo, alquilo inferior o alcoxi inferior, estos grupos son optativamente sustituidos con 1, 2 o 3 átomos de halógeno, NR4R5 en donde R4 y R5 son iguales o diferentes y se seleccionan de; H, alquilo inferior, optativamente sustituido con 1, 2 o 3 grupos seleccionados de halógeno, hidroxilo, ciano y alcoxi inferior, - C(=O)R6 en donde R6 se selecciona de: alquilo inferior optativamente sustituido con OR7 o SR7, o -X1-cicloalquilo optativamente sustituido con OR7, SR7, NR7R8 o con un alquilo de C1-4 lineal o ramificado, en donde R7 y R8 son iguales o diferentes y se seleccionan de hidrógeno o alquilo inferior y X1 es un enlace simple o alquileno de C1-4 lineal o ramificado; R2 se selecciona de: alquilo inferior optativamente sustituido con OR9 SR9 o X2-cicloalquilo optativamente sustituido con OR9, SR9, NR9R10 o con alquilo de C1-4 lineal o ramificado. En donde R9 y R10 son iguales o diferentes y se seleccionan de hidrógeno o alquilo inferior y X2 es un enlace simple o un alquileno de C1-4 lineal o ramificado; -R3 se selecciona de: fórmula (2) en donde: n es un número entero de 1 a 4, Ar es un anillo aromático que comprende 5 o 6 átomos que incluyen de 0 a 3 heteroátomos elegidos de O, S y N, Y1, Y2 e Y 3 que pueden ser idénticos o diferentes, representan: hidrógeno, hidroxilo, mercapto, nitro, halógeno, C(=O)R11, C(=O)R11, C(=O)NR12R13, NR12R13 o -(CH2)s CN en donde s es un número entero de 0 a 2, R11, R12 y R13 se seleccionan de hidrógeno o alquilo inferior, o alquilo inferior o alcoxi inferior, cada uno optativamente sustituido con 1, 2 o 3 átomos de halógeno, o -S(O)mR14 en donde m es 0, 1 o 2 y R14 es un alquilo inferior; y optativamente las formas racémicas y formas isoméricas de este, así como las sales farmacéuticamente aceptables de este, para su uso como medicamento. Una composición farmacéutica que lo comprende y uso de un compuesto de la fórmula (1) para la preparación de un medicamento para la prevención o el tratamiento de enfermedades para las cuales la terapia con un inhibidor de PDE4 es relevante, como cáncer, SIDA y fibrosis.
ARP020103032A 2001-08-13 2002-08-12 Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto. AR036258A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402166A EP1285922A1 (en) 2001-08-13 2001-08-13 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
AR036258A1 true AR036258A1 (es) 2004-08-25

Family

ID=8182851

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103032A AR036258A1 (es) 2001-08-13 2002-08-12 Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto.

Country Status (12)

Country Link
US (1) US6747035B2 (es)
EP (2) EP1285922A1 (es)
JP (1) JP2005502662A (es)
AR (1) AR036258A1 (es)
BR (1) BR0211863A (es)
CA (1) CA2453647A1 (es)
DO (1) DOP2002000447A (es)
HN (1) HN2002000208A (es)
PA (1) PA8552501A1 (es)
PE (1) PE20030344A1 (es)
SV (1) SV2003001173A (es)
WO (1) WO2003016314A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
BRPI0413452A (pt) 2003-08-13 2006-10-17 Takeda Pharmaceutical composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
GEP20135838B (en) 2005-09-14 2013-06-10 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors usage at diabetes treatment
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US8324383B2 (en) * 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (ko) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 2-［6-(3-아미노-피페리딘-1-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2ｈ-피리미딘-1-일메틸］-4-플루오로-벤조니트릴의 용도
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) * 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
DK3310784T3 (da) * 2015-06-17 2020-11-09 Pfizer Tricykliske forbindelser og deres anvendelse som phosphodiesterasehæmmere
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD158549A1 (de) * 1981-05-13 1983-01-19 Karl Kottke Verfahren zur herstellung von 1,4,7,9-verschieden substituierten 4,5-dihydro-s-triazolo(4,3-a)chinazolin-5-onen
IL66835A (en) * 1981-09-24 1988-05-31 Roussel Uclaf 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them
US6492364B1 (en) * 1998-12-04 2002-12-10 Toray Industries, Inc. Triazolo and derivatives as chemokine inhibitors
FR2792938B1 (fr) * 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV

Also Published As

Publication number Publication date
BR0211863A (pt) 2004-09-21
CA2453647A1 (en) 2003-02-27
PA8552501A1 (es) 2003-06-30
US20030069260A1 (en) 2003-04-10
EP1285922A1 (en) 2003-02-26
SV2003001173A (es) 2003-04-03
HN2002000208A (es) 2003-02-27
EP1419159A1 (en) 2004-05-19
DOP2002000447A (es) 2003-02-15
JP2005502662A (ja) 2005-01-27
WO2003016314A1 (en) 2003-02-27
US6747035B2 (en) 2004-06-08
PE20030344A1 (es) 2003-04-10

Similar Documents

Publication Publication Date Title
AR036258A1 (es) Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto.
PL402388A1 (pl) Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BR0210507A (pt) Azaindóis
PE20040999A1 (es) Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas
AR024227A1 (es) Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
AR035505A1 (es) Derivados de naftaleno como compuestos de enlace de receptor canabinoide, procesos para su produccion, su uso como productos farmaceuticos para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada la activacion del receptor canabinoide y composiciones
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
PT1263725E (pt) Novos compostos
UY27368A1 (es) Nuevos compuestos
PA8523201A1 (es) Nueva composicion farmaceutica
SE0101387D0 (sv) Novel compounds
UY27592A1 (es) Nuevo uso
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
ATE495793T1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
GB0310726D0 (en) Therapeutic agents
SE0102716D0 (sv) Novel compounds
SE0102440D0 (sv) New compound
BR0114276A (pt) Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica
BRPI0211025B8 (pt) um novo composto para o tratamento da impotência

Legal Events

Date Code Title Description
FB Suspension of granting procedure